Skip to main content

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting · Phase 2 · NCT06568939

Conditions: Non-Small Cell Lung Cancer, c-MET

At a glance

Research payments reported, 2025
$527,982
U.S. investigators named
25
Sites paid
23
Planned or actual enrollment
150

About the trial

Sponsor
AbbVie
Tested
Telisotuzumab Vedotin (drug)
Dates
Started 2025-01-20; completion 2028-02
Results posted
Not yet

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 …

From ClinicalTrials.gov, last updated 2026-10-22. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $527,982 in research payments for this study in 2025 (77 payments).

Products named: Emrelis

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Valkyrie Clinical Trials Inc $51,029
  • Yale University $47,411
  • Bon Secours Mercy Health Inc $37,800
  • Springfield Clinic LLP $36,349
  • Nho Revive Research Institute LLC $36,116
  • Ironwood Physicians PC $33,095
  • Donald Guthrie Fndn for Education $31,680
  • Renown Regional Medical Center, NV $26,884
  • Genesis Hospital $26,014
  • Texas Oncology $21,292
  • Northwest Georgia Oncology $20,190
  • Ocala Oncology Center Pl $20,000
  • Medical Oncology Associates Ps $19,228
  • Virginia Cancer $19,000
  • Savannah Health Services LLC DBA Memorial Health University Medical Center, GA $17,786
  • Firsthealth of the Carolinas Inc $17,521
  • Titan Health PArtners LLC $15,721
  • University Cancer and Blood Center $15,150
  • Community Cancer Trials of Utah $14,500
  • Cancer Specialists LLC $14,328
  • Boston Imaging Core Lab $3,375
  • Comprehensive Hematology Oncology LLC $2,342
  • Northwest Medical Specialties PLLC $1,171

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.